07 abril 2014

Zeltia : Aplidin®, Yondelis®, PM01183 and PM060184 highlighted at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) .

ZELTIA NEWS:

Aplidin®, Yondelis®, PM01183 and PM060184 highlighted at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) .

Aplidin® confirmed as a first-in-class drug, with the mechanism of action highlighted for the first time, showing it targets the eEF1a protein in tumour cells .

A new study supports the clinical use of PM01183 in Ewing's sarcoma as directed treatment, either alone or in combination with irinotecan .

PM060184 evidences notable antitumour activity in vivo in a range of xenografted tumour types .

Additional Yondelis® data to be presented showing a synergistic combination with Olaparib in breast cancer tumour cell lines .

San Diego, 7 April 2014.- PharmaMar, a biotechnology subsidiary of Grupo Zeltia .

...